Press release
Investigation announced for Long-Term Investors in shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR) over possible Wrongdoing
An investigation on behalf of current long term investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares.
Investors who are current long term investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: ALLR stocks follows a lawsuit filed against Allarity Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: ALLR stocks, concerns whether certain Allarity Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that, the Defendants made false and/or misleading statements and/or failed to disclose tha Defendants had overstated the Dovitinib NDA's continued regulatory prospects, that Allarity and three of its former officers had engaged in illegal, illicit, and/or otherwise improper conduct in connection with the Dovitinib NDA and/or the Dovitinib-DRP PMA, that the foregoing misconduct subjected the Company to an increased risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm, that following Allarity's announcement that it was, in fact, being investigated for wrongdoing in connection with the Dovitinib NDA and/or the Dovitinib-DRP PMA, the Company downplayed the substantial likelihood that an enforcement action would result from such investigation, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR) over possible Wrongdoing here
News-ID: 3925535 • Views: …
More Releases from Shareholders Foundation, Inc.
Investors who hold shares of BioAge Labs, Inc. (NASDAQ: BIOA) Long Term should c …
An investigation was announced for current long-term investors in shares of BioAge Labs, Inc. (NASDAQ: BIOA) concerning potential breaches of fiduciary duties by certain directors of BioAge Labs, Inc.
Investors who are current long term investors in BioAge Labs, Inc. (NASDAQ: BIOA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
e.l.f. Beauty, Inc. (NYSE: ELF) Investor Notice: Deadline in Lawsuit on May 5, 2 …
A deadline is coming up on May 5, 2025 in the lawsuit filed for certain investors of e.l.f. Beauty, Inc. (NYSE: ELF).
Investors who purchased shares of e.l.f. Beauty, Inc. (NYSE: ELF) have certain options and there are strict and short deadlines running. Deadline: May 5, 2025. e.l.f. Beauty, Inc. (NYSE: ELF) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed…
Investigation announced for Long-Term Investors in Revance Therapeutics, Inc. (N …
An investigation was announced for current long-term investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) concerning potential breaches of fiduciary duties by certain directors of Revance Therapeutics, Inc.
Investors who are current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
Skyworks Solutions, Inc. (NASDAQ: SWKS) Shareholder Notice: Deadline in Lawsuit …
The Shareholders Foundation announced that a deadline is coming up on May 5, 2025 in the lawsuit filed for certain investors of Skyworks Solutions, Inc. (NASDAQ: SWKS) over alleged securities laws violations by Skyworks Solutions, Inc.
Investors who purchased shares of Skyworks Solutions, Inc. (NASDAQ: SWKS) have certain options and there are strict and short deadlines running. Deadline: May 5, 2025. Skyworks Solutions, Inc. (NASDAQ: SWKS) stockholders should contact the Shareholders…
More Releases for Allarity
Gastrointestinal Stromal Tumors Pipeline Assessment - FDA, EMA, and PMDA Approva …
Gastrointestinal Stromal Tumors pipeline constitutes 25+ key companies continuously working towards developing 28+ Gastrointestinal Stromal Tumors treatment therapies, analyzes DelveInsight
Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract associated with high rates of malignant transformation. Most GISTs present asymptomatically. They are best identified by computed tomography (CT) scan and most stain positive for CD117 (C-Kit), CD34, and/or DOG-1. There have been many risk stratification classifications systems which are…
Globally, More than 100+ Key Companies are Developing Therapies for Ovarian Canc …
Ovarian cancer is one of the most common cancer in women worldwide and ranks fifth in cancer deaths among women. Ovarian cancer accounts for more deaths than any other female reproductive system cancer. As with most cancers, Ovarian Cancer becomes more common as a person ages. The risk of Ovarian Cancer increases steeply from around 45 years and is greatest in those aged between 75 and 79 years. Between 5…
Temsirolimus Drug Market Size, Share, Analysis, Applications, Growth Insight, Tr …
The temsirolimus drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028).
Temsirolimus drug is used for the treatment of renal cell carcinoma. Renal cell carcinoma is a type of cancer that starts from the kidney. Temsirolimus drug is a type of drug which comes under medications known as kinase inhibitors. Abnormal proteins support cancer cells to multiply, temsirolimus works on those proteins and blocks…
